AIM Immunotech Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Not valued: the figures our models need are missing or failed our data-quality checks.
No model value: free cash flow after stock pay is not positive. How we value companies.
AIM Immunotech Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
AIM Immunotech has little or no product revenue yet; it used $14m of cash in the twelve months to June 2026. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 3 of our 7 financial-health checks.
Our models give no value for AIM Immunotech at present, so past values are not shown.
Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
AIM Immunotech Inc.'s trailing-twelve-month revenue fell 21.5% year on year, with a free-cash-flow margin of -15130.5%. Where it stands out: stock pay as % of revenue of 0.0% ranks 3 of 179 biotechnology companies we cover. Where it lags: free-cash-flow margin of -15130.5% ranks 171 of 176 biotechnology companies we cover.
Current signal Balance sheet growing far ahead of sales: Total assets grew 208% year over year while revenue fell 21% — the balance sheet is expanding 230 points faster than the business it supports.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
We value AIM Immunotech Inc. as an operating company, with every model that fits that kind of business. Cost of equity 12.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.61 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — 0 | Does not apply: no positive value |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare AIM Immunotech Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | $4096.99 | $2944.71 | $1493.70 | $768.19 | $52.38 | $173.62 | $89.23 | $30.07 | $42.68 | $19.40 | $1.10 |
| Market value | $55m | $44m | $29m | $23m | $6m | $166m | $127m | $43m | $62m | $33m | $2m |
| + Net debt (− = net cash) | −$2m | −$2m | $423000 | $5m | $3m | −$36m | −$32m | −$27m | −$5m | $3m | $5m |
| Enterprise value | $53m | $41m | $30m | $29m | $8m | $129m | $95m | $16m | $57m | $36m | $7m |
| Multiples | |||||||||||
| Price / sales | n/m | n/m | 66.8x | 63.1x | 40.9x | n/m | n/m | n/m | n/m | 191.8x | 20.2x |
| Price / earnings | — | — | — | — | — | — | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
Weak moat
How hard AIM Immunotech's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Net income has been a median -56.9% of total assets over 10 years.
Gross margin has been a median -852.7%, moving by 173.6 percentage points (standard deviation) across 5 years.
Operating margin has been a median -12592.5%; its worst year was -15715.9%.
Free cash flow was positive in 0 of 10 years, at a median -9415.7% of revenue.
The diluted share count rose 20158.8% over five years; stock-based pay has been a median 308.2% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (10 before it).
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.78 | +91% | $74000 | −16% |
| Next | −$0.37 | +53% | $50000 | −32% |
The consensus EPS forecast for the current fiscal year is −46.9% on 90 days ago. In the last 30 days, 0 analysts raised AIM Immunotech Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.47 | −$1.47 |
| 60 days ago | −$0.63 | −$0.52 |
| 30 days ago | −$0.63 | −$0.52 |
| 7 days ago | −$0.63 | −$0.52 |
| Now | −$0.78 | −$0.37 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.12 | −$0.43 | −258.3% |
| Mar 2026 | −$0.37 | −$0.69 | −86.5% |
| Dec 2025 | −$0.94 | −$0.44 | +53.1% |
| Sept 2025 | −$0.98 | −$1.57 | −60.2% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| AIM | −49% | −66% | +42% | −55% | −94% | −85% |
| Industry peers (median) | −35% | −56% | −18% | −28% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| AIM | 33% | 8% | 33% | 17% | 25% | 18% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| AIM | −67% | −76% | −48% | −71% | −96% | −89% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from February 23, 2016 to October 30, 2026. Getting back needed a 6486806% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 10, 2026 | −13.8% | −0.3% | −17.2% | −20.7% |
| May 19, 2026 | −39.0% | +0.4% | −2.4% | −7.3% |
| April 16, 2020 | +4.6% | +3.2% | −18.8% | +7.1% |
| October 7, 2019 | +3.6% | −2.0% | +5.5% | −7.3% |
| August 15, 2017 | −15.9% | +0.2% | −18.2% | −25.0% |
| April 3, 2017 | −1.8% | −0.1% | −3.6% | +23.6% |
| November 15, 2016 | −2.2% | +0.6% | −1.1% | −13.3% |
| August 15, 2016 | −11.1% | −0.2% | −5.6% | −38.4% |
| May 16, 2016 | +9.1% | 0.0% | +9.1% | 0.0% |
| March 30, 2016 | 0.0% | +0.2% | 0.0% | +7.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $193K |
| FY23 Q4 | $202K |
| FY24 Q1 | $193K |
| FY24 Q2 | $201K |
| FY24 Q3 | $190K |
| FY24 Q4 | $170K |
| FY25 Q1 | $146K |
| FY25 Q2 | $121K |
| FY25 Q3 | $112K |
| FY25 Q4 | $88K |
| FY26 Q1 | $94K |
| FY26 Q2 | $95K |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | 44.0% |
| FY23 Q4 | 44.3% |
| FY24 Q1 | 23.7% |
| FY24 Q2 | 19.6% |
| FY24 Q3 | -1.6% |
| FY24 Q4 | -15.8% |
| FY25 Q1 | -24.4% |
| FY25 Q2 | -39.8% |
| FY25 Q3 | -41.1% |
| FY25 Q4 | -48.2% |
| FY26 Q1 | -35.6% |
| FY26 Q2 | -21.5% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | -12160.1% |
| FY23 Q4 | -15800.5% |
| FY24 Q1 | -17282.9% |
| FY24 Q2 | -15715.9% |
| FY24 Q3 | -14695.3% |
| FY24 Q4 | -11630.6% |
| FY25 Q1 | -12093.8% |
| FY25 Q2 | -13726.4% |
| FY25 Q3 | -13006.3% |
| FY25 Q4 | -13254.5% |
| FY26 Q1 | -10926.6% |
| FY26 Q2 | -11724.2% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q3 | -9107.8% |
| FY23 Q4 | -10528.2% |
| FY24 Q1 | -11607.3% |
| FY24 Q2 | -11568.2% |
| FY24 Q3 | -10890.0% |
| FY24 Q4 | -8757.6% |
| FY25 Q1 | -8516.4% |
| FY25 Q2 | -9055.4% |
| FY25 Q3 | -11541.1% |
| FY25 Q4 | -12451.1% |
| FY26 Q1 | -12037.2% |
| FY26 Q2 | -15130.5% |
| Fiscal year | 2009 Dec 2009 | 2010 Dec 2010 | 2011 Dec 2011 | 2012 Dec 2012 | 2013 Dec 2013 | 2014 Dec 2014 | 2015 Dec 2015 | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | −0 | −1 | −1 | −2 | −1 | −1 | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −13 | −16 | −14 | −20 | −16 | −18 | −16 | −13 | −10 | −11 | −12 | −14 | −18 | −20 | −32 | −20 | −12 | −11 |
| Operating income | −13 | −16 | −14 | −20 | −17 | −19 | −17 | −14 | −11 | −11 | −12 | −15 | −19 | −20 | −32 | −20 | −12 | −11 |
| Net income | −7 | −13 | −9 | −17 | −16 | −17 | −15 | −8 | −8 | −10 | −9 | −14 | −19 | −19 | −29 | −17 | −14 | −14 |
| Diluted EPS | −$0.02 | −$1760.00 | −$0.28 | −$0.48 | −$0.40 | −$1628.00 | −$1129.33 | −$0.11 | −$0.10 | −$325.67 | −$86.00 | −$15.00 | −$13.33 | −$13.33 | −$0.20 | −$10.31 | −$8.62 | — |
| Growth (year on year) | ||||||||||||||||||
| Revenue | — | +21.6% | +19.3% | +32.3% | −29.6% | +31.3% | −32.5% | −30.8% | +375.0% | −16.0% | −61.9% | +16.4% | −17.2% | +4.4% | +43.3% | −15.8% | −48.2% | −21.5% |
| Margins | ||||||||||||||||||
| Gross margin | −426.1% | −893.3% | −547.8% | −833.8% | −722.7% | −535.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | — | <−999% | <−999% | <−999% |
| Cash flow | ||||||||||||||||||
| Cash from operations | −9 | −12 | −10 | −13 | −17 | −14 | −16 | −7 | −8 | −11 | −9 | −10 | −14 | −16 | −21 | −15 | −11 | −14 |
| Capital spending | 0 | 1 | 2 | 6 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 |
| Free cash flow | −10 | −13 | −12 | −19 | −18 | −14 | −16 | −8 | −8 | −11 | −9 | −10 | −14 | −16 | — | −15 | −11 | −14 |
| Stock-based pay | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 0 | 0 |
| Free cash flow after stock pay | — | −13 | −12 | −19 | −18 | −15 | −16 | −8 | −9 | −12 | −10 | −11 | −16 | −17 | — | −16 | −11 | −14 |
| Balance sheet | ||||||||||||||||||
| Cash | 58 | 3 | 3 | 2 | 1 | 2 | 2 | 2 | 1 | 0 | 1 | 39 | 32 | 27 | 5 | 2 | 3 | 10 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 | 4 | 2 | — | 0 | 0 | 5 | 8 | 4 |
| Net debt (negative = net cash) | −58 | −3 | −3 | −2 | −1 | −2 | −2 | −2 | 0 | 5 | 3 | −36 | −32 | −27 | −5 | 3 | 5 | −6 |
| Diluted shares | — | — | — | — | — | — | — | — | — | — | — | — | 1m | 1m | 1m | 2m | 2m | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 35 | 45 | 16 | 25 | 26 | 21 | 22 | 26 |
| EBITDA | −4,479 | −5,846 | −3,609 | −2,279 | −2,796 | −2,943 | −2,217 | −2,951 |
| Operating income | −4,489 | −5,855 | −3,619 | −2,646 | −2,447 | −2,952 | −2,226 | −3,513 |
| Net income | −3,700 | −5,967 | −3,705 | −2,794 | −3,284 | −4,175 | −3,023 | −3,788 |
| Diluted EPS | −$1.50 | −$2.48 | −$0.01 | −$0.92 | $0.39 | −$0.11 | −$0.17 | −$0.43 |
| Growth (year on year) | ||||||||
| Revenue | −23.9% | −30.8% | −60.0% | −50.0% | −25.7% | −53.3% | +37.5% | +4.0% |
| Margins | ||||||||
| EBITDA margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | — | <−999% | — | <−999% | <−999% | <−999% | <−999% | <−999% |
| Cash flow | ||||||||
| Cash from operations | −3,110 | −3,955 | −2,361 | −1,531 | −5,079 | −1,986 | −2,719 | −4,590 |
| Capital spending | — | 0 | — | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | — | −3,955 | — | −1,531 | −5,079 | −1,986 | −2,719 | −4,590 |
| Stock-based pay | 80 | 196 | 60 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow after stock pay | — | −4,151 | — | −1,531 | −5,079 | −1,986 | −2,719 | −4,590 |
| Last 12 months unless stated | AIM | IBIO | LSTA | CLDX | CLNN | CRVO | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $95000 | $100000 | $100000 | $158000 | $197000 | $331295 | $56m |
| Revenue growth, last 12 months | −21.5% | −75.0% | −90.7% | −97.3% | −31.1% | −95.7% | 12.6% |
| Revenue growth, 3-year average | −17.3% | −62.4% | — | −63.5% | −36.9% | −52.7% | 13.7% |
| Revenue growth, latest quarter | 4.0% | −100.0% | −100.0% | −97.0% | 233.3% | −100.0% | 10.2% |
| Gross margin | −968.5% | 59.9% | 7.7% | — | 70.1% | 100.0% | 82.9% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −189.4% |
| Operating margin, 3-year average | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −363.5% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −169.8% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −168.0% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | <−999% | — | −162.4% |
| Free-cash-flow margin, 3-year average | <−999% | <−999% | <−999% | <−999% | <−999% | — | −310.0% |
| Stock pay / revenue | 0.0% | >999% | >999% | >999% | >999% | 393.0% | 20.0% |
| Change in share count | 49.8% | 13.9% | 5.1% | 4.7% | 35.4% | 8.4% | 8.2% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | -21.5% | 12.6% | 125 of 172 |
| Change in growth rate Growth | +14.1pp | -0.1pp | 40 of 172 |
| Operating margin Profitability | -11724.2% | -189.4% | 169 of 175 |
| Net margin Profitability | -15021.1% | -157.3% | 174 of 180 |
| Free-cash-flow margin Cash generation | -15130.5% | -145.4% | 171 of 176 |
| Stock pay as % of revenue Cash generation | 0.0% | 19.2% | 3 of 179 |
| Long-term debt as % of assets Balance sheet | 28.4% | 20.6% | 51 of 78 |
| Days sales outstanding Balance sheet | 29 days | 75 days | 15 of 100 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Jane Street Group, LLC | $229,439 | 808K | 70.5% | ▲ 3930.0% |
| Virtu Financial LLC | $35,000 | 124K | 10.8% | ▲ 144.2% |
| Morgan Stanley | $14,445 | 51K | 4.4% | ▲ 5787.0% |
| Geode Capital Management, LLC | $13,064 | 46K | 4.0% | ▲ 53.8% |
| Goldman Sachs Group Inc | $9,214 | 32K | 2.8% | New |
| UBS Group AG | $8,216 | 29K | 2.5% | ▲ 2893000.0% |
| Susquehanna International Group, LLP | $6,208 | 22K | 1.9% | New |
| Vanguard Fiduciary Trust Co | $4,975 | 18K | 1.5% | 0.0% |
| Ground Swell Capital, LLC | $3,471 | 12K | 1.1% | New |
| Tower Research Capital LLC (TRC) | $1,326 | 5K | 0.4% | 0.0% |
| Continuum Advisory, LLC | $142 | 1K | 0.0% | New |
| Community Bank, N.A. | $36 | 0K | 0.0% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not AIM Immunotech Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Equels Thomas K CEO & President | October 23, 2026 | Buy | 31,675 | $0.16 | $5,068 |
| Equels Thomas K CEO & President | October 22, 2026 | Buy | 31,250 | $0.16 | $5,094 |
| Equels Thomas K CEO & President | September 17, 2026 | Buy | 24,000 | $0.21 | $5,040 |
| Equels Thomas K CEO & President | September 16, 2026 | Buy | 11,000 | $0.21 | $2,310 |
| Equels Thomas K CEO & President | September 15, 2026 | Buy | 22,000 | $0.22 | $4,840 |
| Equels Thomas K CEO & President | September 14, 2026 | Buy | 5,900 | $0.22 | $1,298 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
